Syros Pharmaceuticals, Inc. Common Stock
SYRS
SYRS was delisted on the 19th of March, 2025.
57 hedge funds and large institutions have $37.8M invested in Syros Pharmaceuticals, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 12 increasing their positions, 14 reducing their positions, and 9 closing their positions.
4,795% more call options, than puts
Call options by funds: $1.08M | Put options by funds: $22K
56% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 9
8% more funds holding
Funds holding: 53 → 57 (+4)
14% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 14
37% less capital invested
Capital invested by funds: $60.1M → $37.8M (-$22.3M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$4.52M |
| 2 |
ACM
Altium Capital Management
New York
|
+$1.37M |
| 3 |
ECM
ExodusPoint Capital Management
New York
|
+$148K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$143K |
| 5 |
LPL Financial
San Diego,
California
|
+$126K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.09M |
| 2 |
PFO
Pathstone Family Office
Englewood,
New Jersey
|
-$282K |
| 3 |
BlackRock
New York
|
-$163K |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$98.4K |
| 5 |
Walleye Capital
New York
|
-$82K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
US Bancorp
Minneapolis,
Minnesota
| $144 | – | – | – |
|
|
HWMA
52
Heritage Wealth Management (Arizona)
Phoenix,
Arizona
| $129 | +$78 | +18 | +100% |
|
53
Dimensional Fund Advisors
Austin,
Texas
| $109 | +$3.05K | +702 | +2% |
|
|
54
Fidelity Investments
Boston,
Massachusetts
| $43 | -$1.09M | -252,017 | -100% |
|
|
PFO
55
Pathstone Family Office
Englewood,
New Jersey
| – | -$282K | -43,826 | Closed |
|
|
56
Walleye Capital
New York
| – | -$82K | -12,800 | Closed |
|
|
ACM
57
Aquatic Capital Management
Chicago,
Illinois
| – | -$5K | -800 | Closed |
|
58
BNP Paribas Financial Markets
Paris,
France
| – | -$3.23K | -502 | Closed |
|
59
Citigroup
New York
| – | -$1K | -111 | Closed |
|
|
CWM
60
CarsonAllaria Wealth Management
Glen Carbon,
Illinois
| – | -$252 | -58 | -36% |
|
61
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$126 | -29 | -81% |
|
|
NA
62
NewEdge Advisors
New Orleans,
Louisiana
| – | +$65 | +15 | New |
|
SYRS Hedge Fund Activity: Q4 2022 in Review
57 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Syros Pharmaceuticals, Inc. Common Stock (SYRS) for Q4 2022, worth a combined $37.8M — down 37% from $60.1M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new SYRS positions and 9 closed out — a net gain of 5 holders — while 12 added to existing stakes and 14 trimmed.
The largest buyer was Bain Capital Life Sciences Investors, adding an estimated $4.52M. The largest seller was Fidelity Investments, cutting an estimated $1.09M.
- 57 institutional investors held Syros Pharmaceuticals, Inc. Common Stock (SYRS) as of Q4 2022, up from 53 in Q3 2022.
- Funds reported $37.8M of Syros Pharmaceuticals, Inc. Common Stock stock for Q4 2022, down 37% quarter-over-quarter.
- 14 funds opened new Syros Pharmaceuticals, Inc. Common Stock positions in Q4 2022 and 9 closed out, a net change of +5 holders.
- The largest Syros Pharmaceuticals, Inc. Common Stock buyer in Q4 2022 was Bain Capital Life Sciences Investors, an estimated $4.52M added.
- The largest Syros Pharmaceuticals, Inc. Common Stock seller in Q4 2022 was Fidelity Investments, an estimated $1.09M sold.
Based on aggregated 13F filings for Q4 2022.